FENC
Fennec Pharmaceuticals Inc.
Biotechnology · Healthcare · United States
10.95
close · 2026-10-29
value
54
cheaper than peers54
quality
80
stronger fundamentals80
ranked against
Biotechnology (commercial)
value
quality
161 peerswide variation
Value inputs
| measure | company | vs peers |
| forward P/E | 11.55× | 78 |
| price to sales | 7.95× | 62 |
| price to book | 9.04× | 23 |
3 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | -0.8% | 78 |
| revenue growth | 72.6% | 74 |
| return on equity | -52.7% | 47 |
3 of 4 measures available
Facts
| market cap | $384M |
| free cash flow | -$2.4M |
| employees | 35 |
| first trade | 2017-09-15 |
| next earnings | 2026-08-11 |
| fundamentals updated | 2026-08-11 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.35 | 0.00 | -0.60 | -0.90 |
| free cash flow | -$12.5M | $27.0M | -$17.1M | -$18.1M |
| net income | -$9.7M | -$436,000 | -$16.0M | -$23.7M |
| revenue | $44.6M | $47.5M | $21.3M | $1.5M |
| unusual items | -$2.0M | -$163,000 | -$34,000 | -$193,000 |